Chemizon to Support Shenogen's Drug Programs | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – South Korean life sciences company Chemizon, a division of Optomagic, said today that it will support Shenogen Pharma Group's drug development programs aimed at developing small molecule therapeutics for cancer and endocrine disorders.

Chemizon will be responsible for a range of services and activities, including lead optimization, assay development, computational chemistry, animal pharmacology, and absorption, distribution, metabolism, and excretion processes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.